Algorithmiq

Algorithmiq develops quantum algorithms and software for drug discovery and pharmaceutical research, focusing on quantum-enhanced molecular simulation and optimization techniques to accelerate the development of new medicines by solving complex computational problems in chemistry and biology that are intractable for classical computers, founded by quantum computing and pharmaceutical industry experts.

Company Information

• Founded: 2020
• Country: Finland
• Website: https://algorithmiq.com
• Categories: quantum pharma

Key People

Sabrina Maniscalco (Co-founder, CEO), Stefan Filipp (Co-founder, CTO)

Aqemia

Aqemia is a next-generation pharmatech company founded in 2019 as a deeptech spinoff from École Normale Supérieure that revolutionizes drug discovery by combining quantum-inspired physics algorithms with generative AI, enabling molecule exploration 10,000 times faster than conventional methods without requiring experimental training data, generating its own molecular data from first principles to guide AI-driven drug candidate discovery, with over $100 million in funding and major partnerships including a $140 million collaboration with Sanofi to accelerate oncology drug development through physics-based molecular design.

GSK Quantum

GlaxoSmithKline (GSK) is advancing quantum computing applications in pharmaceutical research through partnerships with IBM’s Quantum Heron and Condor processors for mRNA codon optimization and clinical data analysis, and collaboration with D-Wave for quantum annealing applications in genetic algorithms. The company worked with Capgemini UK and the National Quantum Computing Centre on quantum-enhanced drug discovery research, developing machine learning pipelines using quantum features for predicting targeted covalent drug reactivity. Led by Ross Walker, Global Director of Scientific Research Computing & Analytics, GSK participates in the QuPharm consortium alongside other major pharmaceutical companies to structure quantum computing’s potential in drug discovery, focusing on optimization problems that exceed traditional computational capabilities in messenger RNA research and therapeutic development.

Menten AI

Menten AI is a pioneering biotechnology company that combines quantum computing, artificial intelligence, and protein engineering to revolutionize drug discovery and design. Founded in 2018 by CEO Vikram Mulligan and leveraging research from the Baker Lab at the University of Washington, the company uses quantum-enhanced algorithms to solve complex protein folding and design problems that are computationally intractable for classical computers. Menten AI’s platform enables the design of novel protein therapeutics, including peptides and small proteins, by exploring vast sequence spaces and optimizing for desired properties such as stability, specificity, and manufacturability. The company’s quantum computing approach provides advantages in sampling complex conformational states and optimizing multi-objective design problems inherent in drug discovery. Menten AI has developed a pipeline of proprietary therapeutic candidates and offers computational design services to pharmaceutical partners. Their technology represents a convergence of quantum computing and biotechnology that could accelerate the development of new medicines for diseases including cancer, autoimmune disorders, and infectious diseases.

Merck Quantum

Merck & Co. explores quantum computing applications for pharmaceutical research, focusing on quantum algorithms for drug discovery, molecular modeling, and clinical trial optimization to accelerate therapeutic development. The company investigates quantum machine learning for analyzing complex biological data, protein-drug interactions, and personalized medicine approaches that could enhance pharmaceutical research capabilities. Merck collaborates with quantum computing companies and research institutions to leverage quantum advantages in computational chemistry, vaccine development, and therapeutic optimization, exploring quantum technologies that could improve drug discovery processes, reduce development timelines, and enhance therapeutic efficacy across oncology, immunology, and infectious disease research programs for advancing global health outcomes.

Novo Nordisk Quantum

Novo Nordisk explores quantum computing applications for pharmaceutical research and drug discovery, investigating quantum algorithms for molecular simulation, protein folding prediction, and drug optimization that could accelerate diabetes and obesity treatment development. The company researches quantum machine learning for analyzing clinical trial data, patient stratification, and personalized medicine approaches, exploring how quantum computing could enhance pharmaceutical research capabilities in endocrinology and metabolic diseases. Novo Nordisk collaborates with quantum computing companies and academic institutions to leverage quantum advantages in computational chemistry, biomarker discovery, and therapeutic development processes, contributing to the pharmaceutical industry’s adoption of quantum technologies for improving drug discovery timelines and therapeutic outcomes in diabetes care and chronic disease management.

Pfizer

Pfizer investigates quantum computing applications for pharmaceutical research and drug discovery, exploring quantum algorithms for molecular modeling, drug design optimization, and clinical trial analytics that could accelerate the development of new vaccines and therapeutic treatments, collaborating with quantum computing companies and academic institutions to leverage quantum simulation capabilities for understanding complex biological systems, protein interactions, and drug mechanisms of action, contributing to the pharmaceutical industry’s adoption of quantum technologies to enhance research productivity, reduce development costs, and improve patient outcomes through more effective drug discovery and personalized medicine approaches.

POLARISqb

POLARISqb is a US quantum biotechnology company founded in 2020 that applies quantum computing and quantum-inspired algorithms to accelerate drug discovery and development, using quantum molecular simulation and optimization techniques to identify novel drug candidates and optimize molecular properties more efficiently than classical computational methods, focusing on leveraging quantum advantage for pharmaceutical applications including drug design, molecular modeling, and therapeutic target identification to reduce drug development timelines and costs.

ProteinQure

ProteinQure leverages quantum molecular simulations and AI to accelerate drug discovery and development, using quantum-enhanced computational methods to model complex molecular interactions and protein dynamics that are challenging for classical computers, enabling more accurate predictions of drug efficacy and safety for pharmaceutical applications.

Company Information

• Founded: 2017
• Country: Canada
• Website: https://proteinqure.com
• Categories: quantum pharma

Key People

Moe Nadeem (Co-founder, CEO), Trent McConaghy (Co-founder)

Related Companies

Explore other quantum computing companies in similar categories or regions.

Qubit Pharmaceuticals

Qubit Pharmaceuticals is a Paris and Boston-based quantum-enhanced drug discovery company founded in 2020 that accelerates pharmaceutical research using hybrid quantum-classical computing through their Atlas platform, achieving molecular simulations 100,000 times faster than traditional methods while reducing drug candidate screening from 5,000 to 200 compounds, with breakthrough technologies including the Hyperion-1 quantum emulator simulating 40 qubits and the FeNNix-Bio1 quantum AI foundation model developed with Sorbonne University, operating one of France’s largest GPU supercomputers and advancing 7 therapeutic programs particularly in oncology and inflammation.

Rahko

Rahko applies quantum machine learning algorithms to drug discovery and pharmaceutical research, developing quantum-enhanced computational methods for molecular analysis, drug-target interactions, and compound optimization that leverage quantum computing’s potential advantages in exploring complex chemical space for therapeutic applications.

Company Information

• Founded: 2018
• Country: UK
• Website: https://rahko.ai
• Categories: quantum pharma

Key People

Nathan Brown (Co-founder, CEO), Leo Canas (Co-founder, CTO)

Related Companies

Explore other quantum computing companies in similar categories or regions.

Roche

Roche explores quantum computing applications for pharmaceutical research and drug discovery, investigating quantum algorithms for molecular simulation, protein folding prediction, and drug-target interaction modeling that could accelerate the development of new medicines and personalized therapies, collaborating with quantum computing companies and research institutions to leverage quantum advantages in computational chemistry, clinical trial optimization, and biomarker discovery, exploring how quantum machine learning and quantum simulation could enhance pharmaceutical research capabilities and reduce drug development timelines while improving therapeutic outcomes for patients across oncology, immunology, and other therapeutic areas.